MeiraGTx

Historical price data

MeiraGTx is a clinical-stage biotech focused on translating advanced genetic medicine into transformative therapies for diseases with high unmet need. Its strategy is built on a fully integrated platform combining novel vector engineering, precision gene control via its riboswitch technology, and in-house GMP manufacturing. Key achievements include a late-stage pipeline with Breakthrough Therapy designation for its xerostomia program and a major strategic collaboration with Eli Lilly in ophthalmology, positioning the company for significant value inflection.

Proprietary platform featuring optimized AAV vector engineering, tissue-specific promoters, and a transformative riboswitch gene regulation system enabling precise, oral small molecule-controlled transgene expression for a wide range of diseases.

MeiraGTx competes in ophthalmology with established gene therapy players like Roche/Spark, but its riboswitch platform is a key differentiator with few direct peers. The Eli Lilly partnership validates its ophthalmology approach. In large chronic diseases, its riboswitch technology positions it against major pharma companies but with a fundamentally different, potentially disruptive modality.